Hematopoietic stem cell (HCT) transplantation offers curative therapy for a variety of malignant and nonmalignant disorders. It is limited by donor availability, transplant related toxicity, graft versus host disease, relapse of malignancy, infections, and for some patients, reduction in post-transplant quality of life. The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) was established in 2001 to develop and execute scientifically meritorious, prospective clinical trials to address these issues. The Network has launched >20 trials with the support of a Data and Coordinating Center (DCC) comprised of a Consortium of the Center for International Blood and Marrow Transplant Research, the National Marrow Donor Program and The EMMES Corporation. The members of this DCC Consortium propose to continue supporting the Network and managing the efficient development, implementation and completion of high-quality Phase l-lll clinical trials for the Network, including concept evaluation and prioritization, protocol development with appropriate statistical designs, timely activation and accrual, monitoring for safety, compliance and data accuracy, and analyzing and disseminating results. The DCC Consortium will coordinate and support all BMT CTN activities maintaining a state-of-the-art database and systems for acquisition and storage of biologic specimens, ensuring data quality, laboratory compliance and adherence to regulatory requirements, managing contractual arrangements and fiscal activities, monitoring and improving center and overall Network performance and supporting all Network committees and activities with meeting planning and other logistical support. The Consortium will also help amplify and leverage Network resources through collaboration with other scientific bodies including National Cancer Institute-funded Cancer Cooperative Groups and the Stem Cell Therapeutic Outcomes Database to maximize successful completion of high quality and high priority clinical trials in HCT.

Public Health Relevance

The proposed Data and Coordinating Center (DCC) will support all activities of the BMT CTN, using the extensive expertise of the investigators in clinical research and transplantation. We will take advantage of collaborations with other organizations and initiatives to maximize efficiency and trial participation. The goal is to complete high quality clinical trials that focus on the most important barriers to transplant success.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZHL1-CSR-K (M5))
Program Officer
Di Fronzo, Nancy L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Medical College of Wisconsin
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Cutler, Corey; Logan, Brent; Nakamura, Ryotaro et al. (2014) Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood 124:1372-7
Lechowicz, M J; Lazarus, H M; Carreras, J et al. (2014) Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. Bone Marrow Transplant 49:1360-5
Pulsipher, Michael A; Chitphakdithai, Pintip; Logan, Brent R et al. (2014) Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation. Blood 123:3655-63
Holter Chakrabarty, Jennifer L; Rubinger, Morel; Le-Rademacher, Jennifer et al. (2014) Autologous is superior to allogeneic hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission. Biol Blood Marrow Transplant 20:1021-5
Roth, Joshua A; Bensink, Mark E; O'Donnell, Paul V et al. (2014) Design of a cost-effectiveness analysis alongside a randomized trial of transplantation using umbilical cord blood versus HLA-haploidentical related bone marrow in advanced hematologic cancer. J Comp Eff Res 3:135-44
Törlén, Johan; Ringdén, Olle; Le Rademacher, Jennifer et al. (2014) Low CD34 dose is associated with poor survival after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 20:1418-25
Jacobsen, Paul B; Le-Rademacher, Jennifer; Jim, Heather et al. (2014) Exercise and stress management training prior to hematopoietic cell transplantation: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902. Biol Blood Marrow Transplant 20:1530-6
Bolaños-Meade, Javier; Logan, Brent R; Alousi, Amin M et al. (2014) Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. Blood 124:3221-7; quiz 3335
Freytes, C O; Vesole, D H; LeRademacher, J et al. (2014) Second transplants for multiple myeloma relapsing after a previous autotransplant-reduced-intensity allogeneic vs autologous transplantation. Bone Marrow Transplant 49:416-21
Wirk, Baldeep; Fenske, Timothy S; Hamadani, Mehdi et al. (2014) Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma. Biol Blood Marrow Transplant 20:951-9

Showing the most recent 10 out of 30 publications